Skip to main content
. 2024 Mar 12;115(5):1665–1679. doi: 10.1111/cas.16143

FIGURE 5.

FIGURE 5

The expression of ITIH5 in benign hepatobiliary diseases and chronic hepatic diseases. (A–F) The expression levels of ITIH5 between the control and case groups in IHCA (GSE11819), liver angioma (GSE62029), PSC (GSE159676), NASH (GSE159676), and other liver diseases (GSE159676), respectively. CLD, chronic liver diseases; IHCA, inflammatory hepatocellular tumor; NASH, nonalcoholic steatohepatitis; PSC, primary sclerosing cholangitis.